May 13, 2020
Amgen Showcases Oncology Pipeline At ASCO 2020
Feb 10, 2020
Janssen Announces Submission to U.S. FDA for New DARZALEX® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
Feb 03, 2020
GSK announces European Medicines Agency (EMA) accepted marketing authorisation application for belantamab mafodotin for the treatment of relapsed or refractory multiple myeloma
Dec 16, 2019
Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/refractory multiple myeloma
Dec 10, 2019
Amgen Data From Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) To Be Presented During Late-Breaking Session At American Society Of Hematology Annual Meeting
Dec 09, 2019
Cancer Drug Revenues Expected to be Largest Share in Pharma Market
Nov 06, 2019
Oncopeptides to Highlight Data From Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019
Sep 13, 2019
Amgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free Survival
Jul 03, 2019
FDA approves new treatment for refractory multiple myeloma
May 16, 2019
Oncopeptides Announces Acceptance of Four Abstracts Highlighting Melflufen Clinical Programs for Presentation at 24th EHA Congress in June 2019
Dec 02, 2018
Oncopeptides Presents First Interim Data From the Ongoing Combination Trial ANCHOR With Melflufen at the 60th American Society of Hematology Meeting
Nov 01, 2018
Amgen To Present New Data Showcasing Extensive Portfolio And Exciting Early Oncology Pipeline At ASH 2018
Nov 01, 2018
Oncopeptides to Present Updated Data From the Two Ongoing Trials ANCHOR and HORIZON in Patients with RRMM at ASH in December 2018
Oct 01, 2018
FDA Approves KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
Aug 27, 2018
Amgen Submits Supplemental New Drug Application For KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone
Jun 01, 2018
Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 mg/m2 KYPROLIS® (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 mg/m2 Regimen In Patients With Relapsed And Refractory Multiple Myeloma
Apr 30, 2018
Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS® (carfilzomib) Label
Jan 30, 2018
Amgen Receives CHMP Positive Opinion To Add Updated Overall Survival Data To KYPROLIS® (carfilzomib) Label
Jan 17, 2018
FDA Approves Addition Of Overall Survival Data To KYPROLIS® (carfilzomib) Label
Jan 17, 2018
Overall Survival Analysis From KYPROLIS® (Carfilzomib) Phase 3 ASPIRE Trial Published in the Journal of Clinical Oncology